LYMPHOID NEOPLASIA Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation
نویسندگان
چکیده
Familial aggregation of Waldenström macroglobulinemia (WM) and related B-cell disorders (BCDs) suggests a role for genetic factors, but few data address environmental influences. We designed a questionnaire-based study to examine clinical and environmental factors in a cohort of WM families with various patterns of case aggregation. We analyzed data on 103 WM patients and 272 unaffected relatives from 35 multiple-case WM and 46 mixed WM/BCD kindred and 28 nonfamilial (sporadic) WM patients, using logistic regression models with generalized estimating equations to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for association. In this study population, the WM disease process appeared similar among patients regardless of family history. Familial WM patients were more likely than unaffected relatives to report a history of autoimmune disease (OR, 2.27; 95% CI 1.214.28) and infections (OR, 2.13; 95% CI 1.25-3.64). Familial WM patients were also more likely to report exposure to farming (OR, 2.70; 95% CI 1.34-5.42), pesticides (OR, 2.83; 95% CI 1.56-5.11), wood dust (OR, 2.86; 95% CI 1.54-5.33), and organic solvents (multiple-case WM OR, 4.21; 95% CI 1.69-10.51) compared with unaffected family members. These data provide clues to both genetic and environmental factors that may influence development of WM. Well-designed casecontrol studies are needed to confirm these findings. (Blood. 2010;115(22): 4464-4471)
منابع مشابه
Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation.
Familial aggregation of Waldenström macroglobulinemia (WM) and related B-cell disorders (BCDs) suggests a role for genetic factors, but few data address environmental influences. We designed a questionnaire-based study to examine clinical and environmental factors in a cohort of WM families with various patterns of case aggregation. We analyzed data on 103 WM patients and 272 unaffected relativ...
متن کاملLYMPHOID NEOPLASIA Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy
Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy Jia Li,1 Daniel M.-Y. Sze,1-3 Ross D. Brown,2 Mark J. Cowley,4 Warren Kaplan,4,5 Sui-Lin Mo,1,6 Shihong Yang,2 Esther Aklilu,2 Karieshma Kabani,2 Yen S. Loh,1 Tetsuo Yamagishi,1 Yuling Chen,1,5 P. Joy Ho,2 and D...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in Sweden
A role for genetic factors in the etiology of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) is implicated based on prior findings from multiply affected families and small case-control and cohort studies. We identified 2144 LPL/WM patients (1539 WM [72%] and 605 LPL [28%]) diagnosed in Sweden, 8279 population-based matched controls, and linkable first-degree relatives of pat...
متن کاملLYMPHOID NEOPLASIA Progression in smoldering Waldenström macroglobulinemia: long-term results
The purpose of this study was to define the risk of progression and survival of patients with smoldering Waldenström macroglobulinemia (SWM). SWM is defined clinically as having a serum monoclonal IgM protein > 3 g/dL and/or > 10% bone marrow lymphoplasmacytic infiltration but no evidence of end-organ damage (anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegal...
متن کاملLYMPHOID NEOPLASIA Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenström macroglobulinemia
Proteasome inhibition represents a valid antitumor approach and its use has been validated in Waldenström macroglobulinemia (WM), where bortezomib has been successfully tested in clinical trials. Nevertheless, a significant fraction of patients relapses, and many present toxicity due to its off-target effects. Selective inhibition of the chymotrypsin-like (CT-L) activity of constitutive proteas...
متن کامل